DK2212423T3 - Onkolytiske koppevirusvektorer - Google Patents
Onkolytiske koppevirusvektorer Download PDFInfo
- Publication number
- DK2212423T3 DK2212423T3 DK08851361T DK08851361T DK2212423T3 DK 2212423 T3 DK2212423 T3 DK 2212423T3 DK 08851361 T DK08851361 T DK 08851361T DK 08851361 T DK08851361 T DK 08851361T DK 2212423 T3 DK2212423 T3 DK 2212423T3
- Authority
- DK
- Denmark
- Prior art keywords
- gly
- leu
- smallpox virus
- virus
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (28)
1. Koppevirus omfattende et defekt F2L-gen, et defekt J2R-gen og en nukleinsyre af interesse, der omfatter et suicidgen.
2. Koppevirus ifølge krav 1, hvor koppevirusset hører til underfamilien Chordopoxvirinae.
3. Koppevirus ifølge krav 2, hvor koppevirusset hører til arten vacciniavirus.
4. Koppevirus ifølge krav 3, hvor koppevirusset er vacciniavirus-stammen WR.
5. Koppevirus ifølge krav 3, hvor koppevirusset er vacciniavirus-stammen Copenhagen.
6. Koppevirus ifølge et hvilket som helst af kravene 1 til 5, hvor suicidgenet koder for et protein med i det mindste en cytosindeaminase-aktivitet.
7. Koppevirus ifølge krav 6, hvor suicidgenet er FCY1, FCA1 eller CodA eller en dermed analog.
8. Koppevirus ifølge krav 6, hvor proteinet med i det mindste cytosindeaminase-aktivitet er det i SEQ ID NO: 2 gengivne polypeptid FCU1-8 og dermed analoge.
9. Koppevirus ifølge et hvilket som helst af kravene 1 til 5, hvori suicidgenet koder for et protein med mindst én cytosindeaminase- og én uracilphosphoribosyltransferase-aktivitet.
10. Koppevirus ifølge krav 9, hvor suicidgenet koder for et polypeptid, der omfatter en aminosyresekvens i det væsentlige som gengivet i SEQ ID NO: 3 (coda::upp), SEQ ID NO: 1 (FCU1) eller aminosyresekvensen FCY1::FUR1.
11. Koppevirus ifølge et hvilket som helst af kravene 1 til 10, hvor koppevirusset endvidere omfatter en nukleinsyresekvens, der omfatter et gen, som koder for en permease.
12. Koppevirus ifølge krav 11, hvor permeasen er en purin- eller en cytosin-permease fra S. cerevisiae.
13. Koppevirus ifølge krav 12, hvor permeasen er valgt fra den gruppe, der omfatter FCY2 og Fur4 og dermed analoge.
14. Koppevirus ifølge et hvilket som helst af kravene 1 til 10, hvor koppevirusset endvidere omfatter de til ekspression af nukleinsyren af interesse nødvendige elementer.
15. Koppevirus ifølge et hvilket som helst af kravene 11 til 13, hvor koppevirusset endvidere omfatter de til ekspression af den nukleinsyresekvens, der omfatter et gen, som koder for en permease, nødvendige elementer.
16. Koppevirus ifølge et hvilket som helst af kravene 1 til 15 til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet.
17. Fremgangsmåde til fremstilling af et koppevirus ifølge et hvilket som helst af kravene 1 til 15, ved hvilken fremgangsmåde: (i) et koppevirus ifølge et hvilket som helst af kravene 1 til 15 indføres i en celle; (ii) cellen dyrkes under betingelser, der er passende til produktion af koppevirusset, og; (iii) koppevirusset udvindes fra cellekulturen.
18. Farmaceutisk sammensætning omfattende et koppevirus ifølge et hvilket som helst af kravene 1 til 15 og et farmaceutisk acceptabelt excipiens.
19. Farmaceutisk sammensætning ifølge krav 18, som endvidere omfatter ét eller flere stoffer, der forstærker den cytotoksiske virkning af 5-fluorcytosin.
20. Farmaceutisk sammensætning ifølge krav 19, hvori de stoffer, der forstærker den cytotoksiske virkning af 5-fluorcytosin, er medikamenter, som inhiberer enzymerne i stofskiftevejen for de novo-biosyntesen af pyrimidiner, fortrinsvis valgt fra den gruppe, der består af PALA, leflunomid og A771726.
21. Lægemiddel ifølge krav 19, hvor det stof, de forstærker den cytotoksiske virkning af 5-fluorcytosin, er methotrexat.
22. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 18 til 21 til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet.
23. Koppevirus til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 16 eller farmaceutisk sammensætning til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 22, hvor proliferationssygdommen er cancer eller restenose.
24. Koppevirus til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 16, eller lægemiddel til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 22, hvor den sygdom, der står i forbindelse med forøget osteoclast-aktivitet, er arthritis rheumatoides eller osteoporose.
25. Farmaceutisk sammensætning til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge et hvilket som helst af kravene 22 til 24, hvor den farmaceutiske sammensætning indgives ad systemisk vej.
26. Farmaceutisk sammensætning til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge et hvilket som helst af kravene 22 til 25, hvor der endvidere indgives et promedikament til værtsorganismen eller-cellen.
27. Farmaceutisk sammensætning til anvendelse ved behandling af en proliferationssygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 26, hvor indgivelsen af promedikamentet foregår mindst 3 dage, fortrinsvis mindst 4 dage og især mindst 5 dage efter indgivelsen af koppevirusset eller sammensætningen.
28. Farmaceutisk sammensætning til anvendelse ved behandling af en proliferations-sygdom eller en sygdom, der står i forbindelse med forøget osteoclast-aktivitet, ifølge krav 27, hvor indgivelsen af promedikamentet foregår 7 dage efter indgivelsen af koppevirusset eller sammensætningen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301556 | 2007-11-19 | ||
| PCT/EP2008/009721 WO2009065547A2 (en) | 2007-11-19 | 2008-11-17 | Poxviral oncolytic vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2212423T3 true DK2212423T3 (da) | 2015-03-16 |
Family
ID=40548531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08851361T DK2212423T3 (da) | 2007-11-19 | 2008-11-17 | Onkolytiske koppevirusvektorer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9180150B2 (da) |
| EP (1) | EP2212423B1 (da) |
| JP (1) | JP5710262B2 (da) |
| KR (1) | KR101542275B1 (da) |
| CN (1) | CN101868546B (da) |
| AU (1) | AU2008328258B2 (da) |
| BR (1) | BRPI0820578A2 (da) |
| CA (1) | CA2705873C (da) |
| CO (1) | CO6210761A2 (da) |
| CR (1) | CR11520A (da) |
| DK (1) | DK2212423T3 (da) |
| EC (1) | ECSP10010287A (da) |
| ES (1) | ES2535633T3 (da) |
| HK (1) | HK1141314A1 (da) |
| HR (1) | HRP20150360T1 (da) |
| IL (1) | IL204539A (da) |
| MX (1) | MX2010005273A (da) |
| NZ (1) | NZ584201A (da) |
| PL (1) | PL2212423T3 (da) |
| RU (2) | RU2557312C2 (da) |
| WO (1) | WO2009065547A2 (da) |
| ZA (1) | ZA201004286B (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110287089A1 (en) | 2009-01-13 | 2011-11-24 | Karola Rittner | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| CA2767458A1 (en) | 2009-07-10 | 2011-01-13 | Bruce Acres | Biomarker for selecting patients and related methods |
| WO2013004658A1 (en) | 2011-07-01 | 2013-01-10 | Transgene Sa | Formulations of 5-fluorocytosine and uses thereof. |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| EP3169341B1 (en) | 2014-07-16 | 2019-06-05 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
| DK3169340T3 (da) * | 2014-07-16 | 2020-11-09 | Roussy Inst Gustave | Kombination af onkolytisk virus med immun-checkpoint-modulatorer |
| US10517943B2 (en) | 2014-12-01 | 2019-12-31 | Transgene S.A. | Stable liquid vaccinia virus formulations |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| EP3283088A4 (en) | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| JP7034080B2 (ja) | 2016-02-25 | 2022-03-11 | メモリアル スローン ケタリング キャンサー センター | ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 |
| CA3015650A1 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| CN110199018B (zh) * | 2016-08-09 | 2024-06-07 | 希望之城 | 嵌合痘病毒组合物及其用途 |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| JP7391831B2 (ja) * | 2017-08-11 | 2023-12-05 | シティ・オブ・ホープ | Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用 |
| WO2019148109A1 (en) * | 2018-01-26 | 2019-08-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| SG11202106898VA (en) | 2018-12-28 | 2021-07-29 | Transgene Sa | M2-defective poxvirus |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| EP1367128A1 (en) * | 1991-03-07 | 2003-12-03 | Connaught Technology Corporation | Genetically engineered vaccine strain |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU5446700A (en) * | 1999-05-28 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US6897057B1 (en) * | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| DE602004018927D1 (de) * | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| KR101542276B1 (ko) * | 2007-11-19 | 2015-08-06 | 트랜스진 에스.에이. | 폭스바이러스성 온콜리틱 벡터 |
-
2008
- 2008-11-17 RU RU2013129678/10A patent/RU2557312C2/ru not_active IP Right Cessation
- 2008-11-17 KR KR1020107010821A patent/KR101542275B1/ko active IP Right Grant
- 2008-11-17 JP JP2010533511A patent/JP5710262B2/ja not_active Expired - Fee Related
- 2008-11-17 MX MX2010005273A patent/MX2010005273A/es active IP Right Grant
- 2008-11-17 DK DK08851361T patent/DK2212423T3/da active
- 2008-11-17 NZ NZ584201A patent/NZ584201A/en not_active IP Right Cessation
- 2008-11-17 CN CN2008801168337A patent/CN101868546B/zh not_active Expired - Fee Related
- 2008-11-17 AU AU2008328258A patent/AU2008328258B2/en not_active Ceased
- 2008-11-17 EP EP08851361.9A patent/EP2212423B1/en not_active Not-in-force
- 2008-11-17 PL PL08851361T patent/PL2212423T3/pl unknown
- 2008-11-17 US US12/743,412 patent/US9180150B2/en not_active Expired - Fee Related
- 2008-11-17 RU RU2010124613/10A patent/RU2508401C2/ru not_active IP Right Cessation
- 2008-11-17 BR BRPI0820578-7A patent/BRPI0820578A2/pt not_active Application Discontinuation
- 2008-11-17 CA CA2705873A patent/CA2705873C/en not_active Expired - Fee Related
- 2008-11-17 ES ES08851361.9T patent/ES2535633T3/es active Active
- 2008-11-17 WO PCT/EP2008/009721 patent/WO2009065547A2/en active Application Filing
-
2010
- 2010-03-16 IL IL204539A patent/IL204539A/en active IP Right Grant
- 2010-06-17 ZA ZA2010/04286A patent/ZA201004286B/en unknown
- 2010-06-18 EC EC2010010287A patent/ECSP10010287A/es unknown
- 2010-06-18 CR CR11520A patent/CR11520A/es not_active Application Discontinuation
- 2010-06-18 CO CO10073787A patent/CO6210761A2/es not_active Application Discontinuation
- 2010-08-17 HK HK10107869.1A patent/HK1141314A1/xx not_active IP Right Cessation
-
2015
- 2015-03-30 HR HRP20150360TT patent/HRP20150360T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2212423T3 (da) | Onkolytiske koppevirusvektorer | |
| DK2212345T3 (da) | Onkolytiske poxvirus-vektorer | |
| AU2015243297B2 (en) | Poxviral oncolytic vectors | |
| US9687515B2 (en) | Poxviral oncolytic vectors |